Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 24, Issue 2, Pages 163-173Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2012.09.001
Keywords
Interleukine-6; Cancer; Inflammatory diseases; Siltuximab; Tocilizumab
Categories
Ask authors/readers for more resources
Interleukin (IL)-6 is a pro-inflammatory cytokine that produces multifunctional effects. Deregulated IL-6 production and signaling are associated with chronic inflammatory diseases, auto-immunity and cancer. On this basis, inhibition of IL-6 production, its receptors or the signaling pathways are strategies currently being widely pursued to develop novel therapies for a wide range of diseases. This survey aims to provide an updated account of why IL-6 inhibitors are shaping up to become an important class of drugs potentially useful in the treatment of ailments and in particular in inflammation and cancer. In addition we discuss the role of different agents in modulating IL-6 and also recent clinical studies targeting IL-6 in inflammation-mediated diseases and cancer. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available